Biological
IM19 clinical trials
Also written IM19.
- studies test it
- 11
- open now
- 4
- in phase 3
- 0
- first study started
- 2016
Keep track of what changes. Save the IM19 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- IM19
- 3
Studies by the year they started
11 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 7
- Phase 2
- 5
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Beijing Immunochina Medical Science & Technology Co., Ltd. (10) · Peking University Third Hospital (1)
Studies
Open first, then newest update. How each study uses IM19 is read from its arms, and is right about nine times in ten.
Testing it · 11
- IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)RecruitingNot applicablePeking University Third HospitalNCT06513429Written as IM19 CAR-T cells
- IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy PatientsNot yet recruitingEarly Phase 1Beijing Immunochina Medical Science & Technology Co., Ltd.NCT06690359Written as IM19 chimeric antigen receptor T cell injection
- Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1/2Beijing Immunochina Medical Science & Technology Co., Ltd.NCT05309213Written as IM19 CAR-T cells
- Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) PatientsRecruitingPhase 1/2Beijing Immunochina Medical Science & Technology Co., Ltd.NCT04440436Written as IM19 CAR-T Cells
- Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic LeukemiaStatus unknownEarly Phase 1Beijing Immunochina Medical Science & Technology Co., Ltd.NCT05480501Written as IM19 CAR-T cells
- Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell LymphomaStatus unknownPhase 1/2Beijing Immunochina Medical Science & Technology Co., Ltd.NCT05155215Written as IM19 CAR-T cells
- Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After TransplantationStatus unknownNot applicableBeijing Immunochina Medical Science & Technology Co., Ltd.NCT04336501Written as IM19 CAR-T
- Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)CompletedPhase 1/2Beijing Immunochina Medical Science & Technology Co., Ltd.NCT03173417Written as IM19 CAR-T
- Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL PatientsStatus unknownPhase 1Beijing Immunochina Medical Science & Technology Co., Ltd.NCT03528421Written as IM19
- Safety and Efficacy Evaluation of IM19 CAR-T CellsStatus unknownPhase 1/2Beijing Immunochina Medical Science & Technology Co., Ltd.NCT03142646Written as IM19 CAR-T
- Safety and Efficacy Evaluation of IM19 CellsStatus unknownPhase 1Beijing Immunochina Medical Science & Technology Co., Ltd.NCT03344705Written as IM19 CAR-T